Date: Sat, 24 Feb 2001 11:58:04 -0500
From: Michael Belkin

Subject: GlaxoSmithKline's Strong Performance from Key Therapy Areas and New
 Products Drives Earnings Per Share Growth to 16% in Sterling (14% CER)

"Vaccines increased 11 percent to $1,280 million -- New vaccines,
accounting for 63 percent of the total vaccine portfolio, were up 20
percent, boosted by the performance of Infanrix, the company's DTPa
(diphtheria, tetanus and pertussis) range of combination vaccines --
growing at 47 percent."     ...

Pharmaceutical sales by therapeutic area

                                               2000

--------------------------------------------------------
                         Total               USA
Europe         RoW
                       $m    CER%    $m  CER% $m   CER% $m   CER%

VACCINES   1,280     11     322      (5)    593     11     365     29
Hepatitis           702       (3)    255     (4)     319     (3)   128
(2)
Infanrix              260       47      53       59    149     34
58     84

http://biz.yahoo.com/prnews/010221/glaxosmithkline_earns.html
Content-Type: text/html; charset=iso-8859-1;
 name="glaxosmithkline_earns.html"
Content-Disposition: inline;
 filename="glaxosmithkline_earns.html"
Content-Base: "http://biz.yahoo.com/prnews/010221/gla
xosmithkline_earns.html"
Content-Location: "http://biz.yahoo.com/prnews/010221/gla
xosmithkline_earns.html"

Yahoo! Finance Finance Home - Yahoo! - Help
----------
PR Newswire

Click Here!

[ Latest Headlines | Market Overview | News Alerts ]


----------
  Datek Online. Apply Now 
Datek Online. Apply Now
Related Quotes
GSK
55.65
-0.84
delayed 20 mins - disclaimer
Wednesday February 21, 7:05 am Eastern Time

Press Release

SOURCE: GlaxoSmithKline plc

GlaxoSmithKline's Strong Performance from Key Therapy Areas and New
Products Drives Earnings Per Share Growth to 16% in Sterling (14% CER)


HIGHLIGHTS


- Pharmaceutical sales up 10 percent


- Sales growth in key therapy areas: CNS 16 percent, Respiratory 15
percent, Anti-virals 14 percent


- New products contributed nearly $1.5 billion in growth, up 60 percent


- Avandia sales of $702 million


- Seretide sales of $316 million, US launch of Seretide/Advair planned for
April 2001


- Business performance profits before tax up 11 percent; EPS up 14 percent


LONDON, Feb. 21 /PRNewswire/ -- GlaxoSmithKline plc (NYSE: GSK - news;
``GSK'') today announces its results for the year ended December 31, 2000,
summarized below. The merger of Glaxo Wellcome (``GW'') and SmithKline
Beecham (``SB'') was completed on December 27, 2000, and the results for
2000 reflect the combined results of the separate GW and SB businesses in
2000.
                      2000 BUSINESS PERFORMANCE RESULTS

                               2000          1999       Increase
                                $m            $m          CER%
    Total Sales                27,480        26,186          9
    Trading Profit              7,640         7,133         12
    Profit Before Tax           8,097         7,627         11
    Earnings Per ADR            $1.85         $1.71         14


Business performance results exclude merger items and restructuring costs.
Growth rates are at constant exchange rates (CER) unless otherwise stated.
1999 sales and trading profit exclude Healthcare Services.

Commenting on the performance for the year, Jean-Pierre Garnier, Chief
Executive Officer, said:

``These results, achieved while we were separate companies, demonstrate the
strength and performance of the two organizations we have brought together
to form GSK. Clearly our employees remained focused on maintaining the
momentum of our separate businesses, despite the distraction of integration
planning, and delivered excellent results. I'm particularly pleased by the
performance of Seretide and Avandia. The business is in good shape and GSK
is off to a strong start.''

Fourth quarter 2000 -- Sales growth in the fourth quarter was 4 percent,
essentially reflecting the impact of wholesaler stocking in the third
quarter in the USA. Key products, such as Paxil, Augmentin and Wellbutrin,
achieved significantly higher growth in prescription volume than in
reported sales, indicating that underlying business performance in the
fourth quarter remained strong.

Pharmaceuticals

Pharmaceutical sales of $23,452 million were 85 percent of total sales and
grew at 10 percent. With sales of over $4 billion, new products represent
17 percent of pharmaceutical sales and grew 60 percent.

Pharmaceutical sales in the USA, which represents half of GSK's total
pharmaceutical business, grew 15 percent driven by strong performances from
all major products. In Europe, pharmaceutical sales growth was 6 percent,
while the rest of the world (RoW) was up 8 percent.

Strong growth from key therapy areas: CNS growth driven by Seroxat/Paxil --
In GSK's largest sales category, CNS, excellent growth of 16 percent to
$4,984 million was driven by an outstanding performance from Seroxat/Paxil,
which increased by 17 percent to $2,356 million. During 2000, Paxil became
the market leader in the US SSRI (selective serotonin reuptake inhibitor)
market in new retail prescriptions. Paxil benefited throughout the world
from its new indication for Social Anxiety Disorder. GSK's strategy of
broadening the label for new indications continued with filings for
Generalized Anxiety Disorder and Post Traumatic Stress Disorder, and the
expected launches during 2001 will contribute to further growth of Paxil in
the USA. In Europe, where Seroxat continues to be the number one
antidepressant, its sales grew by 11 percent to $508 million, while in the
RoW growth was 29 percent to $242 million. Paxil was launched in Japan at
the end of 2000 and is off to a strong start.

Wellbutrin for depression also made a significant contribution to GSK's
strong CNS performance. In the USA, sales grew 19 percent, and worldwide
sales amounted to $687 million. In the company's migraine portfolio --
which achieved sales of $1,189 million, up 5 percent -- Imigran/Imitrex
remains the global market leader with sales of $1,072 million.

Lamictal for epilepsy grew strongly -- 28 percent to $439 million worldwide
and 34 percent in the USA to $210 million -- owing to additional
promotional resources in the USA.

Three key Respiratory products -- Seretide, Flixotide, and Serevent --
contributed $623 million in growth -- In the Respiratory therapy area,
Flixotide/Flovent, up 29 percent to $1,338 million, continues to be the
world's leading treatment for asthma. US sales growth of 57 percent
represents an outstanding performance. Seretide achieved sales of $316
million, and continues to be successfully launched in markets around the
world. Further Seretide growth will be driven by its US launch planned for
April under the trade name Advair. The company expects Seretide/Advair to
become the treatment of choice for persistent asthma.

Anti-viral leadership continued with the launch of Trizivir, the first
triple combination treatment for HIV/AIDS -- The growth of GSK's HIV
products, up 14 percent to $1,740 million, contributed strongly to the
performance of the company's Anti-viral therapy area. Combivir grew 21
percent to $854 million, while Trizivir, the first triple combination HIV
therapy, was launched in the USA in December 2000 and subsequently in the
UK, France and Switzerland. Strong performances from Ziagen and Agenerase,
with combined sales of over $300 million, reflect the broadness of the HIV
portfolio. In the herpes franchise, Valtrex, up 32 percent to $368 million,
gained significant market share owing to the convenience of its once-daily
dosing.

Confirmed success of Avandia drove the Metabolic & GI business -- Avandia
for the treatment of Type 2 diabetes continues to fulfill its outstanding
potential, achieving sales of $702 million. With sales in the US of $658
million and a 55 percent market share, Avandia has been prescribed to over
1.7 million patients. In 2001, further growth is expected from Avandia as
it continues to rollout in Europe and RoW. Lotronex, a treatment for
irritable bowel syndrome, was launched in the USA in March 2000 and
generated sales of $55 million before being withdrawn in November 2000.

Augmentin retained momentum in Anti-bacterials, with long-term
opportunities for growth -- The highlight of the performance in the Anti-
bacterial therapy area was Augmentin in the USA, where it grew by 13
percent to $1,102 million, benefiting from increased awareness of its
effectiveness in treating drug-resistant bacteria. Worldwide, Augmentin
achieved total sales in 2000 of $1,853 million, up 8 percent.

Vaccines increased 11 percent to $1,280 million -- New vaccines, accounting
for 63 percent of the total vaccine portfolio, were up 20 percent, boosted
by the performance of Infanrix, the company's DTPa (diphtheria, tetanus and
pertussis) range of combination vaccines -- growing at 47 percent.

Consumer Healthcare

Consumer Healthcare sales grew 3 percent; trading profit grew 7 percent --
In the USA, consumer sales decreased 3 percent, reflecting the impact of
private label smoking control products and a mild 'flu season.

Worldwide sales of Oral Care products rose 6 percent to $976 million, with
sales growth of 13 percent in the Aquafresh product line. Nutritional
Healthcare products increased 9 percent to $813 million. Sales growth was
primarily driven in the UK by the strength of Lucozade `Sport' and by the
success of Ribena. Worldwide sales of over-the-counter (OTC) medicines
totalled $2,210 million, down 1 percent primarily owing to an 8 percent
decline in the smoking control franchise.

Consumer Healthcare set to benefit from Block Drug acquisition -- In
January 2001, GSK completed the acquisition of Block Drug, the manufacturer
of Sensodyne toothpaste and other oral healthcare and consumer products,
for $1.24 billion. This strategic acquisition will enhance the Consumer
Healthcare performance through a significant increase in sales and sales
synergies through geographic expansion of major brands, significant cost
savings, and other improvements in trading margins.

Dividend

Both GW and SB had already announced dividends for the period up to 31st
December 2000. GW will pay a second interim dividend and SB a fourth
interim dividend on 17th April 2001.

GSK -- one of the world's leading research-based pharmaceutical and
healthcare companies -- is committed to improving the quality of human life
by enabling people to do more, feel better and live longer. For company
information, visit GSK on the World Wide Web at www.gsk.com.      Inquiries:

    UK Media Inquiries                Martin Sutton      (020) 8966 8000
                                     Philip Thomson     (020) 8966 8000
                                     Alan Chandler      (020) 8975 2290

    US Media Inquiries                Nancy Pekarek       (215) 751 7709
                                     Mary Anne Rhyne     (919) 483 2839

    European Analyst/Investor
     Inquiries                        Jennie Younger     (020) 8966 8378
                                     Duncan Learmouth   (020) 8966 5961
                                     Joan Toohill       (020) 8966 8715
                                     Anita Kidgell      (020) 8966 8369

    US Analyst/ Investor
     Inquiries                        Frank Murdolo       (212) 308 5185
                                     Tom Curry           (215) 751 5419


GSK prepares its results in pounds sterling. Accordingly, the results
announcement is issued in pounds sterling and is available on ``Corporate
Home'' at www.gsk.com. This document is a convenience translation in US$.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation
Reform Act of 1995, GSK cautions investors that any forward-looking
statements or projections made by GSK, including those made in this
Announcement, are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Factors that may affect
GSK's operations include generic and brand competition for existing
products, ability to integrate the businesses and realize synergies and
cost savings, difficulties and uncertainties inherent in new product
development, pricing pressures, changes in government laws and regulations,
efficacy or safety concerns over marketed products, adverse outcome of
material legal proceedings, changes in tax laws, and economic factors over
which GSK has no control including changes in inflation, interest rates and
foreign currency exchange rates and controls.
PROFIT AND LOSS ACCOUNT
                                     2000

                                                  Merger,
                                               restructuring
                               Business        and disposal of
                             performance        subsidiaries         Total
                        ----------------------------------------------------
                         2000      1999         2000    1999     2000     1999
                           $m        $m   CER%    $m      $m       $m        $m
                        -----     -----  ----- -----  -----    -----     -----
    SALES
    Retained businesses
      * Pharma-
         ceuticals     23,452     22,061  10       -       -   23,452   22,061
      * Consumer
         Healthcare     4,028      4,125   3       -       -    4,028    4,125
                       ------     ------       -----  -----   -------  -------
                       27,480     26,186   9       -       -   27,480   26,186
      * Healthcare
        Services             -      1,024            -       -        -     1,024
                      -------    -------       -----  -----  -------   -------
    Total Sales        27,480     27,210           -       -   27,480   27,210
                      -------    -------       -----  -----  -------   -------
    Cost of sales      (5,793)   (5,669) (8)   (230)  (646)  (6,023)  (6,315)
    Selling,
     general and
     administration   (10,232)   (9,723) (9)    (614)   (71) (10,846)  (9,794)
    Research and
     development       (3,815)    (3,702) (7)    (24)     -    (3,839)  (3,702)
                      -------    -------       -----  -----  -------   -------
    Operating costs
     - retained
     businesses       (19,840)   (19,094)       (868)  (717) (20,708) (19,811)
                      -------    -------       -----  -----  -------   -------
    Operating costs
     - Healthcare
     Services                -       (983)           -    (49)        -   (1,032)

    TRADING PROFIT
    Retained businesses
      * Pharma-
         ceuticals       6,963     6,436  13     (800)  (685)   6,163    5,751
      * Consumer
         Healthcare        677       656    7     (68)   (32)     609       624
                      -------    -------       -----  -----  -------   -------
                        7,640      7,092  12    (868)  (717)    6,772    6,375
      * Healthcare
         Services            -         41            -    (49)        -       (8)
                      -------    -------       -----  -----  -------   -------
    Total Trading
     Profit              7,640      7,133  12    (868)  (766)    6,772    6,367

    Other operating
     income/(expense)     416        669            -       -      416       669
                      -------    -------       -----  -----  -------   -------
    Operating profit    8,056     7,802         (868)  (766)   7,188     7,036
    Disposal of
     associates            219         63            -       -      219        63
    Profits/(losses)
     of associates         99         24          (12)   (13)       87       11
    Divestments              -          -        2,131     15     2,131       15
    Merger transaction
     costs                   -          -         (184)     -      (184)       -
                      -------    -------       -----  -----  -------   -------
    Profit before
     interest            8,374      7,889  11   1,067   (764)    9,441    7,125
    Net interest
     payable              (277)      (262)          -       -     (277)    (262)
                      -------    -------       -----  -----  -------   -------
    PROFIT BEFORE
     TAXATION            8,097      7,627  11   1,067   (764)    9,164    6,863

    Taxation            (2,210)   (2,150)        (372)   176   (2,582)   (1,974)
                      -------    -------       -----  -----  -------   -------
    Profit after
     taxation            5,887      5,477  12     695   (588)    6,582    4,889
    Minority interests   (183)     (178)           -      -      (183)    (178)
    Preference share
     dividends             (85)       (79)           -      -       (85)     (79)
                      -------    -------       -----  -----  -------   -------
    EARNINGS             5,619      5,220  13     695   (588)    6,314    4,632
                      =======    =======       =====  =====  =======   =======
    EARNINGS PER ADR    $1.85     $1.71   14                    $2.08     $1.51
                      =======    =======                      =======   =======



To illustrate ``Business performance'', merger items and restructuring
costs in 2000 and restructuring costs and business disposals in 1999 have
been excluded and an adjusted EPS presented.

Appropriations of profit attributable to shareholders are set out under
``Appropriations''.                             PROFIT AND LOSS ACCOUNT
                                   Q4 2000

                                                  Merger,
                                               restructuring
                               Business        and disposal of
                             performance        subsidiaries         Total
                        ----------------------------------------------------
                           Q4        Q4            Q4     Q4        Q4       Q4
                         2000      1999         2000    1999     2000     1999
                           $m        $m   CER%    $m      $m       $m        $m
                        -----     -----  ----- -----  -----    -----     -----
    SALES
    Retained businesses
      * Pharma-
         ceuticals       6,319     6,388    5       -      -    6,319     6,388
      * Consumer
         Healthcare     1,064      1,154   (1)     -       -    1,064    1,154
                       ------     ------       -----  -----    ------   ------
                        7,383      7,542    4      -       -    7,383    7,542
      * Healthcare
         Services            -          7            -       -        -         7
                       ------     ------       -----  -----    ------   ------
    Total Sales         7,383      7,549            -       -    7,383    7,549
                       ------     ------       -----  -----    ------   ------
    Cost of sales      (1,538)   (1,612)   (1)  (134)  (271)  (1,672)  (1,883)
    Selling,
     general and
     administration    (2,726)   (2,865)    2   (271)   (29)  (2,997)  (2,894)
    Research and
     development       (1,052)    (1,107)  (2)   (20)     -    (1,072)  (1,107)
                       ------     ------       -----  -----    ------   ------
    Operating costs
     - retained
     businesses        (5,316)    (5,584)       (425)  (300)  (5,741)   (5,884)
                       ------     ------       -----  -----    ------   ------
    Operating costs
     - Healthcare
     Services                -         (7)           -    (39)        -      (46)

    TRADING PROFIT
    Retained businesses
      * Pharma-
         ceuticals       1,858     1,786   14    (422)  (274)   1,436    1,512
      * Consumer
         Healthcare        209       172    29     (3)   (26)     206       146
                       ------     ------       -----  -----    ------   ------
                        2,067      1,958   15   (425)  (300)    1,642    1,658
      * Healthcare
         Services            -          -            -    (39)        -      (39)
                       ------     ------       -----  -----    ------   ------
    Total Trading
     Profit              2,067      1,958   15   (425)  (339)    1,642    1,619

    Other operating
     income/(expense)     222        310            -       -      222       310
                       ------     ------       -----  -----    ------   ------
    Operating profit    2,289     2,268         (425)  (339)   1,864     1,929
    Disposal of
     associates             (3)         -            -       -       (3)        -
    Profits/(losses)
     of associates         20         39           (1)   (13)       19       26
    Divestments              -          -        2,131     15     2,131       15
    Merger transaction
     costs                   -          -         (113)     -      (113)       -
                       ------     ------       -----  -----    ------   ------
    Profit before
     interest            2,306      2,307    9  1,592   (337)    3,898    1,970
    Net interest
     payable               (64)       (85)           -      -       (64)     (85)
                       ------     ------       -----  -----    ------   ------
    PROFIT BEFORE
     TAXATION            2,242      2,222   10  1,592   (337)    3,834    1,885

    Taxation              (612)      (619)       (489)     58   (1,101)    (561)
                       ------     ------       -----  -----    ------   ------
    Profit after
     taxation            1,630      1,603   11  1,103   (279)    2,733    1,324
    Minority interests    (50)       (46)           -      -       (50)     (46)
    Preference share
     dividends             (22)       (21)           -      -       (22)     (21)
                       ------     ------       -----  -----    ------   ------
    EARNINGS             1,558      1,536   12  1,103   (279)    2,661    1,257
                       ======     ======       =====  =====    ======   ======
    EARNINGS PER ADR    $0.51     $0.51    12                   $0.88     $0.41
                       ======     ======                       ======    ======


To illustrate ``Business performance'', merger items and restructuring
costs in 2000 and restructuring costs in 1999 have been excluded and an
adjusted EPS presented.                     Pharmaceutical sales by
therapeutic area

                                               2000
                     --------------------------------------------------------
                         Total            USA           Europe           RoW
                        $m    CER%      $m   CER%      $m   CER%     $m   CER%
                     ------------    ------------  ------------   -----------

    CNS               4,984      16   3,507     15  1,031      16    446     28
    Depression       3,043      17   2,272     18     508     11    263      31
    Seroxat/Paxil    2,356     17    1,606     18    508      11    242     29
    Wellbutrin         687      19     666     19       -      -      21     58

    Migraine         1,189       5     894       5    231      -      64     11
    Imigran/Imitrex  1,072      3      824      4    193      (2)    55      6
    Naramig/Amerge     117     20       70     20     38      15      9     51

    Lamictal            439      28     210     34     176     20     53      35
    Requip               88      20      40     19      46     20      2      26
    Zyban               175      54      91       1     52   >100      32
 23

    RESPIRATORY      4,239      15   1,705     26  1,698       9    836     10
    Flixotide/
     Flovent         1,338      29     629     57     464      2    245      49
    Serevent            945       8     502     24     385     (6)    58      14
    Seretide            316   >100        -      -     272   >100     44
  >100
    Flixonase/
     Flonase            620      16     447     18      68     10    105      14
    Ventolin            521      (7)     47    (21)    226     (5)   248     (6)
    Becotide            312    (25)       6    (82)   231     (12)    75    (40)

    ANTI-BACTERIALS  3,758      2    1,736      7  1,072     (4)    950      1
    Augmentin        1,853       8   1,102     13     486     (3)   265       9
    Zinnat/Ceftin      654       -     310     (7)    172      3    172      10
    Fortum              324      (9)     61    (17)    134     (1)   129    (14)
    Amoxil              302       1      79      55     93    (18)    130      -

    ANTI-VIRALS      2,886      14   1,394     17     807     13    685      12
    HIV               1,740      14   1,043     16     525     18    172      (9)
    Trizivir             11    >100       9   >100       2   >100
 -      -
    Combivir            854      21     524     17     263     38     67      (5)
    Epivir              470      (7)    250      -     152     (9)    68     (22)
    Retrovir             92     (30)     38    (22)     35    (35)    19    (33)
    Ziagen              234      75     152     46      67   >100     15
>100
    Agenerase            79     60       70     52       6     81       3
>100

    Herpes              936       5     286     14     246      1    404       3
    Valtrex             368      32     224     24      88     22     56
>100
    Zovirax             568      (7)     62    (12)    158     (8)   348     (6)

    Zeffix              106    >100       8   >100      10   >100
88   >100
    Relenza              49      97      21     29       9     51     19
>100

    METABOLIC &
     GASTRO-
     INTESTINAL      1,873      33     903   >100     377    (13)   593
  3
    Avandia             702    >100     658   >100      12   >100
32   >100
    Zantac              874     (11)    181    (18)   287     (16)   406     (4)
    Lotronex             55    >100      55   >100       -      -       -
     -

    VACCINES         1,280      11     322     (5)    593     11    365      29
    Hepatitis          702      (3)    255     (4)    319     (3)   128     (2)
    Infanrix            260      47      53     59     149     34     58      84

    ONCOLOGY &
     EMESIS           1,079     11      758     12    196       9    125     10
    Zofran              746      13     514     15     141     12     91       6
    Hycamtin            144       1      96      (5)    35      6      13     40

    CARDIOVASCULAR     704       -     429     (8)    182     19     93      10
    Coreg               225      11     225     17       -      -       -      -

    ARTHRITIS
     (Relafen)         319     (28)    278    (30)    26      (7)    15    (23)
    DERMATOLOGICALS    378     (4)      53    (20)    94      (5)   231      -
    OTHER             1,272      (2)    260     (6)    346     (7)   666       2
                    -------------   -------------  ------------  ------------
    TOTAL SALES
     CONTINUING
     BUSINESS       22,772      11  11,345     15  6,422       6  5,005      9

    Divested
     products           680     (2)     367     (1)    65      (5)   248     (3)
    Famvir              231      11     174     20      27    (13)    30      (5)
    Kytril              333      (7)    187    (14)     38      1    108       2
    Other               116      (9)      6    (40)      -      -    110      (7)
                    -------------   -------------  ------------  ------------
    TOTAL
     PHARMACEUTICAL
     SALES           23,452     10   11,712     (3) 6,487      6   5,253      8
                    =============   =============  ============  ============



                   Pharmaceutical sales by therapeutic area

                                              Q4 2000
                     --------------------------------------------------------
                         Total            USA           Europe           RoW
                        $m    CER%      $m   CER%      $m   CER%     $m   CER%
                     ------------    ------------  ------------   -----------

    CNS               1,337       5     931       1    276      7     130     31
    Depression         801       3     583     (1)    137      -     81      45
    Seroxat/Paxil      617       -     405     (5)    137      -     75      45
    Wellbutrin         184      12     178     11       -      -       6     48

    Migraine            327       -     254       2     55    (10)     18     14
    Imigran/Imitrex    296      -      236      2     45     (12)    15     11
    Naramig/Amerge      31       4      18       4     10     (2)      3     42

    Lamictal            120      20      61     26      45     14     14      16
    Requip               25       3      12       6     14       1     (1)     -
    Zyban                53      76      22    (12)     21   >100     10
 66

    RESPIRATORY      1,185      14     502     25     448      7    235       9
    Flixotide/
     Flovent            391      28     205     64     113     (6)    73      36
    Serevent            270      10     157     30     100     (8)    13      (1)
    Seretide            114   >100        -      -      93   >100     21
  >100
    Flixonase/
     Flonase            152       5     113       5     14       4     25       4
    Ventolin            142    (10)      16    (20)    58      (8)    68     (8)

    Becotide             73     (34)     (2) >(100)    57     (19)    18
(41)

    ANTI-BACTERIALS  1,060     (7)     532     (3)   285    (12)    243     (9)
    Augmentin          547      (2)    350      4     130    (12)    67      (6)
    Zinnat/Ceftin      200      (4)    104     (9)     50      4     46      (2)
    Fortum               82     (16)     15    (30)     32    (11)    35    (16)
    Amoxil               76     (19)     16      3      25    (35)    35     (10)

    ANTI-VIRALS        792      11     384     11     199      4    209      18
    HIV                 471      12     284     13     135     13     52       -
    Trizivir             11    >100       9   >100       2   >100
 -      -
    Combivir            233      18     141     16      70     23     22      16
    Epivir              125      (3)     70      6      36     (7)    19     (20)
    Retrovir             23     (22)     10    (16)      8    (26)     5     (27)
    Ziagen               60      31      38     13      18     64      4      82
    Agenerase            19       -      16    (11)      1     41      2
>100

    Herpes              249       3      81      16     55     (8)    113      2
    Valtrex             115      51      64     28      22     19     29
>100
    Zovirax             134     (18)     17    (13)     33    (19)    84    (19)

    Zeffix               34    >100       4   >100       2   >100
28   >100
    Relenza              18     (23)      1    (93)      1    (76)    16
>100

    METABOLIC & GASTRO-
     INTESTINAL        501      23     238     86      95    (11)   168       2
    Avandia             206    >100     187   >100       6   >100
13   >100
    Zantac              224     (16)     42    (33)     70    (16)   112     (8)
    Lotronex              6    >100       6   >100       -      -       -
     -

    VACCINES            314       5      76      17    143     (8)     95     23
    Hepatitis          165     (10)     61      7      73    (21)    31      (6)
    Infanrix             67      20      14     88      37     12     16       8

    ONCOLOGY & EMESIS  295     11      211     16     48      (2)    36
   6
    Zofran              198      13     138     18      35      6     25       3
    Hycamtin             42      (1)     30      1       9    (11)     3      24

    CARDIOVASCULAR     180     (3)     109    (12)    45      18     26      3
    Coreg                59      23      59     23       -      -       -      -

    ARTHRITIS (Relafen) 71    (31)      62    (30)     6     (40)     3    (31)
    DERMATOLOGICALS     98     (5)      14    (17)    22      (2)    62     (3)
    OTHER               336       8      72      26     90    (11)    174     16
                     ------------    ------------  ------------  ------------
    TOTAL SALES
     CONTINUING
     BUSINESS        6,169       6   3,131      9   1,657     (1) 1,381      8

    Divested
     products           150    (26)      63    (40)    14     (18)    73    (11)
    Famvir               45     (23)     32    (25)      5    (27)     8     (10)
    Kytril               70     (32)     30    (51)      9    (11)    31      (8)
    Other                35     (15)      1    (40)      -      -     34     (14)
                     ------------    ------------  ------------  ------------
    TOTAL
     PHARMACEUTICAL
     SALES            6,319       5   3,194      7   1,671     (1) 1,454      7
                     ============    ============  ============  ============
 

SOURCE: GlaxoSmithKline plc

Email this story - Most-emailed articles - Most-viewed articles


----------
More Quotes and News:GlaxoSmithKline PLC (NYSE:GSK - news)
Related News Categories: earnings, medical/pharmaceutical

----------
Help


----------
Copyright 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of
Service

Copyright 2001 PR Newswire. All rights reserved. Republication or
redistribution of PRNewswire content is expressly prohibited without the
prior written consent of PRNewswire. PRNewswire shall not be liable for any
errors or delays in the content, or for any actions taken in reliance thereon.
Questions or Comments?